(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Candel Therapeutics's earnings in 2026 is -$54,422,000.On average, 9 Wall Street analysts forecast CADL's earnings for 2026 to be -$69,877,827, with the lowest CADL earnings forecast at -$75,395,076, and the highest CADL earnings forecast at -$56,930,976. On average, 9 Wall Street analysts forecast CADL's earnings for 2027 to be -$50,336,654, with the lowest CADL earnings forecast at -$139,301,378, and the highest CADL earnings forecast at $26,926,813.
In 2028, CADL is forecast to generate $34,363,742 in earnings, with the lowest earnings forecast at -$122,786,267 and the highest earnings forecast at $307,735,004.